China-based MindRank’s oral glucagon-like peptide-1 receptor agonist (GLP-1RA) has achieved up to 10.5% weight loss in a ...

Rezpegaldesleukin, an IL-pathway agonist and regulatory T-cell (Treg) proliferator, was being investigated in the REZOLVE-AD ...

Teva Pharmaceutical has reported the final analysis of the PEARL Phase IV migraine prevention trial of Ajovy (fremanezumab).

Neuron23 has dosed the first subject in the global Phase II NEULARK trial of NEU-411 for early Parkinson's disease (PD).

The FDA's new genAI-assisted scientific review technology, named Elsa, was officially adopted by the agency on 2 June.

The COMP005 study (NCT05624268) evaluated a placebo against COMP360, a synthetic, proprietary formulation of psilocybin, for ...

NKGen Biotech has activated two new trial sites in Canada and Florida for the Phase I/IIa study of troculeucel to treat ...

Cidara Therapeutics has reported encouraging top-line outcomes from the Phase IIb NAVIGATE trial of the investigational ...

Vertex Pharmaceuticals has shared data from the Phase I/II segment of the Phase I/II/III FORWARD-101 trial, evaluating ...

Eli Lilly is looking to approach regulatory approval of efsitora alfa (efsitora), its once-weekly insulin for type 2 diabetes ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial.

Lundbeck’s Vyepti (eptinezumab) has met both the primary and secondary endpoints in the placebo-controlled Phase IV ...